1. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis

   • Huifang Wang
   • Nanchen Zhang
   • Yuping Gong

   Review Article 21 November 2019 Pages: 2629 - 2639

   

2. New insights inside the interdigitating dendritic cell sarcoma—pooled analysis and review of literature

   • Amr Muhammed
   • Ahmed R. H. Ahmed
   • Esraa Elnakib

   Review Article 18 November 2019 Pages: 2641 - 2651

   

3. Non-invasive urinary biomarkers of renal function in sickle cell disease: an overview

   • Marília Rocha Laurentino
   • Sérgio Luiz Arruda Parente Filho
   • Romélia Pinheiro Gonçalves Lemes

   Review Article 23 October 2019 Pages: 2653 - 2660

   

4. CRISPR/Cas9 gene correction of HbH-CS thalassemia-induced pluripotent stem cells

   • Xie Yingjun
   • Xie Yuhuan
   • Sun Xiaofang

   Original Article Open access 09 September 2019 Pages: 2661 - 2671

   

5. Genetic modulators of fetal hemoglobin expression and ischemic stroke occurrence in African descendant children with sickle cell anemia

   • Marta Nicolau
   • Sofia Vargas
   • Paula Faustino

   Original Article 02 September 2019 Pages: 2673 - 2681

   

6. Acute porphyrias: a German monocentric study of the biochemical, molecular genetic, and clinical data of 62 families

   • Olivia Bronisch
   • Thomas Stauch
   • Petro E. Petrides

   Original Article 19 November 2019 Pages: 2683 - 2691

   

7. Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis

   • Philipp Riffel
   • Mohamad Jawhar
   • Andreas Reiter

   Original Article 05 November 2019 Pages: 2693 - 2701

   

8. Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms

   • Martin Kirschner
   • Anne Bornemann
   • Steffen Koschmieder

   Original Article 20 November 2019 Pages: 2703 - 2709

   

9. Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission—a multi-center historical control study

   • Tamar Berger
   • Uri Rozovski
   • Ofir Wolach

   Original Article 11 September 2019 Pages: 2711 - 2717

   

10. Residual methylation of tumor suppressor gene promoters, RASSF6 and RASSF10, as novel biomarkers for minimal residual disease detection in adult acute lymphoblastic leukemia

    • Samareh Younesian
    • Sepideh Shahkarami
    • Seyed H. Ghaffari

    Original Article 05 September 2019 Pages: 2719 - 2727

    

11. Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study

    • Vanja Zeremski
    • Kathleen Jentsch-Ullrich
    • Enrico Schalk

    Original Article 08 November 2019 Pages: 2729 - 2737

    

12. Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index

    • Sung Kyun Yim
    • Ho-Young Yhim
    • Jae-Yong Kwak

    Original Article 11 November 2019 Pages: 2739 - 2748

    

13. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia

    • Gilles Salles
    • Emmanuel Bachy
    • Michael Doubek

    Original Article Open access 19 November 2019 Pages: 2749 - 2760

    

14. Socioeconomic Position is Positively Associated with Monoclonal Gammopathy of Undetermined Significance in a Population-based Cohort Study

    • Börge Schmidt
    • Elisabeth Debold
    • Lewin Eisele

    Original Article 06 November 2019 Pages: 2761 - 2767

15. Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma

    • Ningning Wang
    • Nahom Tesfaluul
    • Baohong Yue

    Original Article 20 November 2019 Pages: 2769 - 2780

    

16. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group

    • Sini Luoma
    • Pekka Anttila
    • Raija Silvennoinen

    Original Article Open access 31 October 2019 Pages: 2781 - 2792

    

17. Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-α

    • Weiwei Zhao
    • Wei Wang
    • Ying Wang

    Original Article 25 October 2019 Pages: 2793 - 2803

    

18. Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial

    • Tomoaki Fujisaki
    • Takayuki Ishikawa
    • Koji Nagafuji

    Original Article Open access 16 October 2019 Pages: 2805 - 2814

    

19. Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group

    • Kiyotaka Izumi
    • Junya Kanda
    • Akifumi Takaori-Kondo

    Original Article 12 November 2019 Pages: 2815 - 2823

    

20. Aggressive systemic mastocytosis: a diagnostic challenge in a patient with myotonic dystrophy type 2: a case report

    • Christin Le Hoa Tran
    • Nadja Jaekel
    • Haifa Kathrin Al-Ali

    Letter to the Editor 09 November 2019 Pages: 2825 - 2827

    

21. A new SH2D1A mutation in a female adult XLP disease with hemophagocytic lymphohistiocytosis and NK-cell leukemia

    • Jin-Hua Liang
    • Hua-Yuan Zhu
    • Wei Xu

    Letter to the Editor 22 November 2019 Pages: 2829 - 2831

    

22. Secondary haploidentical hematopoietic stem cell transplantation in patients with relapse or graft failure after initial hematopoietic stem cell transplantation

    • Chang Hou
    • Nan Chen
    • Depei Wu

    Letter to the Editor 18 November 2019 Pages: 2833 - 2836

    

23. Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma

    • Carlos Bravo-Perez
    • Inmaculada Pajares
    • Francisco Jose Ortuño

    Letter to the Editor 11 November 2019 Pages: 2837 - 2839

    

24. Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis

    • Kazuhisa Chonabayashi
    • Yoshinori Yoshida
    • Akifumi Takaori-Kondo

    Letter to the Editor 14 November 2019 Pages: 2841 - 2843

    

25. Response to interferon treatment in essential thrombocythemia with inv(3)(q21q26)

    • Radhika Gangaraju
    • Andrew J. Carroll
    • Josef T. Prchal

    Letter to the Editor 01 November 2019 Pages: 2845 - 2846

    

26. Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia

    • Anna Maria Peri
    • Raffaella Rossio
    • Flora Peyvandi

    Letter to the Editor 18 November 2019 Pages: 2847 - 2849

    

27. Unexpected response of extramedullary plasmacytoma in patients with lung cancer who received nivolumab

    • Ou Yamaguchi
    • K. Kaira
    • H. Kagamu

    Letter to the Editor 16 November 2019 Pages: 2851 - 2852

    

28. Hemoglobin Kirklareli [Α₂ 59(E7) His>Leu; HBA2:c.176A>T] in a Brazilian child with severe dyspnea and low O₂ saturation

    • G. A. Pedroso
    • P. Fernandes
    • M. F. Sonati

    Letter to the Editor 11 November 2019 Pages: 2853 - 2855

29. Correction to: prediction of thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria

    • Yuzhou Huang
    • Xinjian Liu
    • Bing Han

    Correction 15 November 2019 Pages: 2857 - 2857